Reported Earlier, Avidity Biosciences Prices $300.1M Upsized Public Offering Of 7,320,000 Common Stock At $41/Share
Reported Earlier, Avidity Biosciences Prices $300.1M Upsized Public Offering Of 7,320,000 Common Stock At $41/Share
The gross proceeds to Avidity from the offering, before deducting the underwriting discounts and commissions and other offering expenses, are expected to be approximately $300.1 million. The offering is expected to close on or about August 16, 2024, subject to the satisfaction of customary closing conditions.
Avidity intends to use the net proceeds from this offering, together with its existing cash, cash equivalents and marketable securities, to fund the development of its clinical programs, to advance research and development associated with its AOC platform and for working capital and general corporate purposes.
在扣除承銷折扣和佣金以及其他發行費用之前，預期Avidity將從此次發行中獲得的總收益約爲300.10萬美元。預計該發行將於2024年8月16日左右結束，視符合慣常的結算條件而定。
Avidity計劃將本次發行的淨收益與其現有現金、現金等價物和可流通證券資金一起，用於資助其臨床項目的開發、推進與AOC平台相關的研究和開發以及用於營運資金和一般企業用途。
